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See Article, pages 75–82Patients with advanced cirrhosis and ascites or oedema cannot
only avidly retain sodium but also solute-free water due to renal
abnormalities that occur in the natural course of the disease.
With time, solute-free water retention leads to a dilutional or
hypervolemic state where water is retained in excess of sodium,
causing hyponatraemia, and hypoosmolality [1]. The main path-
ogenic factor responsible for hyponatraemia in this setting is a
non-osmotic hypersecretion of arginine vasopressin (AVP, or
antidiuretic hormone) from the neurohypophysis related to cir-
culatory dysfunction. In cirrhosis hyponatraemia is deﬁned as a
serum sodium concentration of less than 130 mEq/L in the pres-
ence of ascites or oedema [2,3]. Although in most cases hypona-
traemia occurs in cirrhosis in association with renal impairment,
it also is associated with hepatic encephalopathy [4]. However,
the mechanisms responsible for the relationship with hepatic
encephalopathy have not been fully elucidated.
Hyponatraemia in cirrhosis has gained attention in the last
decade due to the fact that a number of studies have shown that
it correlates with poor prognosis. Recent studies also indicate
that hyponatraemia is an important marker of prognosis in
patients awaiting liver transplantation and may be associated
with an increased morbidity, particularly neurological complica-
tions, and reduced survival after transplantation [5–9]. Therefore,
it is not surprising that experts recommend correction of serum
sodium levels in patients with cirrhosis and hyponatraemia
[2,3]. However, the classic recommended ﬂuid restriction strat-
egy of 1.5 L/day rarely works in these patients [3]. Yet, the use
of vaptans in cirrhosis, which act by antagonizing speciﬁcally
the effects of AVP on the V2 receptors, located in the kidney
tubules, is associated with a marked increase in renal solute-free
water excretion and improvement of hyponatraemia [10,11].
That said, there are several issues when considering therapy for
patients with hyponatraemia and cirrhosis. First, whom should
we treat? Should we treat all patients with hyponatraemia or
those with symptoms and sodium levels <125 mEq/L? PerhapsJournal of Hepatology 20
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Open access under CC BY-NC-ND license.the latter, as it is suggested by EASL guidelines, but this is based
on expert opinion and not driven by data [2]. Second, are we just
treating a number? Since currently we have no good data that
demonstrate a beneﬁcial effect of vaptans or any other measure
that improves serum sodium on hard outcomes, such as clinical
events (i.e. ascites, hepatic encephalopathy, infections, or out-
come after liver transplantation) or mortality, this question
becomes highly relevant. Third, the data on vaptans have only
proven to be beneﬁcial in short-term studies and in addition
these drugs may be associated with severe adverse events (i.e.
severe dehydration or hepatotoxic effects).
Despite these potential drawbacks, we now know that hyp-
onatraemia has a negative impact on the quality of life (QOL) in
patients with cirrhosis and ascites. This is no question an impor-
tant marker, as many patients with hyponatraemia have a poor
QOL and some have associated hepatic encephalopathy. In fact
a cross sectional study of 523 patients with cirrhosis, complicated
by ascites, demonstrated that the health related quality of life
(HRQOL) was signiﬁcantly decreased in patients with hyponatra-
emia and serum sodium levels of less than 130 mEq/L [12]. This
effect was independent of disease severity, marked by liver fail-
ure or increased MELD score. In addition, recent data indicate
that hyponatraemia is a strong predictor of poor HRQOL, inde-
pendent of overt cognitive dysfunction, and this may be
improved following withdrawal of diuretics in the subgroup of
patients whose serum sodium responds to this intervention
[13]. So, improvement of HRQOL is therefore a desirable outcome
and perhaps changes in HRQOL and cognition could be recog-
nized as strong end points in cirrhosis, however this needs to
be adequately studied. Until now, changes in HRQOL in cirrhosis
had not been adequately analysed because these effects can be
cumbersome to measure in the clinical setting.
In this issue Ahluwalia et al. [14], delve into this matter and
thus the authors should be commended for doing so, as this area
can be considered arid by many hepatologists. In the study, the
authors enrolled 24 patients with cirrhosis and hyponatraemia
with prior episodes of hepatic encephalopathy of whom 17
received tolvaptan and 14 completed the study over two weeks.
Patients had a complete evaluation before starting tolvaptan
(serum sodium, cognition, HRQOL, brain MRI and companion bur-
den) and the same tests were repeated 2 weeks after the drug15 vol. 62 j 13–14
Editorial
treatment. Not surprisingly serum sodium and urine free water
clearance increased with tolvaptan without changes in mental
status or liver function. Interestingly, cognitive function, HRQOL
and companion burden improved in these 14 patients after tol-
vaptan. In addition on MRI and magnetic resonance spectroscopy
there was reduced total brain and white matter volume, increase
in choline, and reduced cytotoxic oedema. These ﬁndings are rel-
evant because they not only demonstrated changes in the HRQOL
score but also changes in functional MRI. Patients that had prior
episodes of hepatic encephalopathy underwent a battery of tests
that improved after tolvaptan therapy.
Hyponatremic and hepatic encephalopathy may coexist in
patients with cirrhosis. The clinical picture is a confusional syn-
drome, but minimal manifestations, detectable by psychometric
tests, can also be seen in both conditions. In cirrhotic patients,
subclinical cognitive deﬁcits are very frequent, especially in those
with previous episodes of overt hepatic encephalopathy. At vari-
ance with overt hepatic encephalopathy, covert hepatic encepha-
lopathy is considered a chronic alteration, a dementia more than
a delirium and the search for associated triggering conditions is
seldom considered [15]. The improvement in psychometric tests
after tolvaptan therapy suggests that also in patients with sub-
clinical cognitive alterations the search and treatment of condi-
tions, which may act as a trigger, is crucial. Another interesting
ﬁnding of this study is the reduction of venous ammonia by tol-
vaptan treatment. In cirrhosis, the kidney may act as a net ammo-
nia producer or excretor [16], and up until now, urinary ammonia
excretion did not increase by the infusion of plasma expander
[17]. Although not directly proven in the study by Ahluwalia
et al. [14], in which urinary ammonia excretion was not mea-
sured, tolvaptan could also, by means of increasing the urine
ﬂow, stimulate this neglected mechanism of ammonia disposal.
The results of this study certainly shed light on the beneﬁcial
effects of improving serum sodium levels in patients with cirrho-
sis. This strategy allows not only to treat at a threshold of
130 mEq/L (which is what we have been doing), but improves
important end points, such as HRQOL and cognition, with evi-
dence on functional neuroimaging. Based on these ﬁndings we
can conclude that improvement of hyponatraemia can after all
beneﬁt patients, perhaps only on the HRQOL and cognition mea-
sures, but this is undoubtedly a leap forward in the ﬁeld, as we
can now move ahead and not only treat according to a number
patients with cirrhosis and hyponatraemia.Conﬂict of interest
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